|4.35||+0.1100||+2.59%||Vol 769.38K||1Y Perf 62.45%|
|Nov 29th, 2023 16:00 DELAYED|
|- -||-0.03 -0.69%|
|Target Price||5.25||Analyst Rating||Moderate Buy 1.80|
|Potential %||20.69||Finscreener Ranking||★★★ 49.22|
|Insiders Trans % 3/6/12 mo.||-/-/67||Value Ranking||★★ 45.54|
|Insiders Value % 3/6/12 mo.||-/-/99||Growth Ranking||+ 30.86|
|Insiders Shares Cnt. % 3/6/12 mo.||-/-/99||Income Ranking||— -|
|Price Range Ratio 52W %||88.86||Earnings Rating||Strong Sell|
|Market Cap||1.33B||Earnings Date||7th Nov 2023|
Today's Price Range
|Moving Averages:||Strong Buy|
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||-|
|Estimated EPS Next Report||0.10|
|EPS Growth Next 5 Years %||-|
|Avg. Weekly Volume||684.85K|
|Avg. Monthly Volume||958.73K|
|Avg. Quarterly Volume||1.18M|
Amneal Pharmaceuticals Inc. Class A (NYSE: AMRX) stock closed at 4.35 per share at the end of the most recent trading day (a 2.59% change compared to the prior day closing price) with a volume of 769.38K shares and market capitalization of 1.33B. Is a component of indices and it is traded on NYSE exchange. The company belongs in the Drug Manufacturers industry, Healthcare sector and employs 5500 people. Amneal Pharmaceuticals Inc. Class A CEO is Chintu Patel / Chirag Patel.
The one-year performance of Amneal Pharmaceuticals Inc. Class A stock is 62.45%, while year-to-date (YTD) performance is 118.59%. AMRX stock has a five-year performance of -75.44%. Its 52-week range is between 1.24 and 4.74, which gives AMRX stock a 52-week price range ratio of 88.86%
Amneal Pharmaceuticals Inc. Class A currently has a PE ratio of -2.50, a price-to-book (PB) ratio of 1.13, a price-to-sale (PS) ratio of 0.21, a price to cashflow ratio of 2.20, a PEG ratio of -0.10, a ROA of -3.65%, a ROC of -1.40% and a ROE of -44.42%. The company’s profit margin is -15.53%, its EBITDA margin is 6.00%, and its revenue ttm is $1.60 Billion , which makes it $10.58 revenue per share.
Of the last four earnings reports from Amneal Pharmaceuticals Inc. Class A, there were 4 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $0.10 for the next earnings report. Amneal Pharmaceuticals Inc. Class A’s next earnings report date is -.
The consensus rating of Wall Street analysts for Amneal Pharmaceuticals Inc. Class A is Moderate Buy (1.8), with a target price of $5.25, which is +20.69% compared to the current price. The earnings rating for Amneal Pharmaceuticals Inc. Class A stock is Strong Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Amneal Pharmaceuticals Inc. Class A has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Amneal Pharmaceuticals Inc. Class A has a Buy technical analysis rating based on Technical Indicators (ADX : 16.20, ATR14 : 0.22, CCI20 : 28.99, Chaikin Money Flow : 0.06, MACD : 0.10, Money Flow Index : 52.64, ROC : 4.82, RSI : 54.21, STOCH (14,3) : 54.17, STOCH RSI : 0.34, UO : 48.24, Williams %R : -45.83), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Amneal Pharmaceuticals Inc. Class A in the last 12-months were: Alva Emily (Option Excercise at a value of $0), Anastasios G. Konidaris (Option Excercise at a value of $0), Andrew S. Boyer (Option Excercise at a value of $0), Boyer Andrew (Option Excercise at a value of $0), Boyer Andrew (Sold 29 302 shares of value $121 017 ), Deborah Autor (Option Excercise at a value of $0), J. Kevin Buchi (Option Excercise at a value of $0), Jason B. Daly (Sold 0 shares of value $0 ), Kiely John (Option Excercise at a value of $0), Nark Ted (Option Excercise at a value of $0), Nikita Shah (Option Excercise at a value of $0), Patel Gautam (Option Excercise at a value of $0), Shah Nikita (Option Excercise at a value of $0), Yanai Shlomo (Option Excercise at a value of $0)
Copyright © 2016-2023 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
General partner of Finscreener is SLOVAKODATA, a.s.
This could take some time, please wait.